ESMO 2018: Melanoma highlights

Source: Ecancer, November 2018

Dr Teresa Amaral speaks with Will Davies at ESMO 2018 in Munich about essential news from melanoma trials.

She highlights the data underlying surgical standards and new classifications in melanoma following presentations at ASCO 2018, and emerging data from the neoadjuvant setting including OPACIN-neo and combination immunotherapies.

She also highlights the triplet therapy of dabrafenib and trametinib with pembrolizumab in the Keynote022 trial, as presented by Prof Paolo Ascierto.